TY - JOUR
T1 - Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans
AU - Klaassen, Zachary
AU - Stock, Shannon
AU - Waller, Justin
AU - De Hoedt, Amanda
AU - Freedland, Stephen J.
N1 - Funding Information:
reported grant funding from the US Department of Defense, as well as advisory board involvement with Bayer, Astellas/Pfizer, Myovant/Pfizer, and Blue Earth Diagnostics outside the submitted work. Ms De Hoedt reported grants from Janssen, Genomic Health, Ferring, Merck, LungLife AI, Blue Earth Diagnostics, Myriad, DiaSorin, MDxHealth, and Pfizer outside the submitted work. No other disclosures were reported.
Publisher Copyright:
© 2022 American Medical Association.
PY - 2022/6
Y1 - 2022/6
N2 - IMPORTANCE Several studies have assessed the negative effect of the COVID-19 pandemic on cancer screening and diagnosis rates. However, this has not been evaluated for prostate biopsy and prostate cancer (PC) diagnosis in an equal-access health care system. OBJECTIVE To determine the association of the pandemic with prostate biopsy and PC diagnosis rates among Black vs White patients in the Veterans Affairs Health Care System (VAHCS). DESIGN, SETTING, AND PARTICIPANTS This cohort study included a retrospective analysis of all prostate biopsies performed on patients in the VAHCS without a preexisting PC diagnosis between January 2018 and March 2021. The base population included all living male patients who had at least 1 visit to the VAHCS during the 3 years prior to each month of the study. EXPOSURE The COVID-19 pandemic. MAIN OUTCOMES AND MEASURES The main outcomes were the number of prostate biopsies and PC diagnoses by month. The influence of the pandemic on prostate biopsy volume and the incidence of PC diagnoses was modeled using an interrupted time-series analysis. Poisson generalized linear models were fitted to project the expected number of prostate biopsies and PC diagnoses had there been no pandemic interruption. Additional models were used to test for differences by race. RESULTS Prior to the pandemic (January 2018 through February 2020), monthly biopsy numbers among 51 606 included men ranged between 1230 and 1695, of which 56% to 60% of results were positive for PC. The estimated number of missed PC diagnoses from March 2020 through March 2021 ranged from 97 cases (October 2020: 752 cases expected, 655 cases observed) to 573 cases (April 2020: 794 cases expected, 221 cases observed). Prior to the pandemic, biopsy rates were statistically significantly higher among Black vs White men (incidence rate ratio, 2.25; 95% CI, 2.06-2.46; P < .001). There was no change in biopsy rates associated with race at the onset of the pandemic nor during the recovery period from March 2020 to March 2021. Similar trends were observed for PC diagnosis rates. CONCLUSIONS AND RELEVANCE Results of this cohort study demonstrate that during the COVID-19 pandemic, prostate biopsy and PC diagnosis rates decreased, particularly during the peak of the pandemic. However, there were no statistically significant changes in rates by race.
AB - IMPORTANCE Several studies have assessed the negative effect of the COVID-19 pandemic on cancer screening and diagnosis rates. However, this has not been evaluated for prostate biopsy and prostate cancer (PC) diagnosis in an equal-access health care system. OBJECTIVE To determine the association of the pandemic with prostate biopsy and PC diagnosis rates among Black vs White patients in the Veterans Affairs Health Care System (VAHCS). DESIGN, SETTING, AND PARTICIPANTS This cohort study included a retrospective analysis of all prostate biopsies performed on patients in the VAHCS without a preexisting PC diagnosis between January 2018 and March 2021. The base population included all living male patients who had at least 1 visit to the VAHCS during the 3 years prior to each month of the study. EXPOSURE The COVID-19 pandemic. MAIN OUTCOMES AND MEASURES The main outcomes were the number of prostate biopsies and PC diagnoses by month. The influence of the pandemic on prostate biopsy volume and the incidence of PC diagnoses was modeled using an interrupted time-series analysis. Poisson generalized linear models were fitted to project the expected number of prostate biopsies and PC diagnoses had there been no pandemic interruption. Additional models were used to test for differences by race. RESULTS Prior to the pandemic (January 2018 through February 2020), monthly biopsy numbers among 51 606 included men ranged between 1230 and 1695, of which 56% to 60% of results were positive for PC. The estimated number of missed PC diagnoses from March 2020 through March 2021 ranged from 97 cases (October 2020: 752 cases expected, 655 cases observed) to 573 cases (April 2020: 794 cases expected, 221 cases observed). Prior to the pandemic, biopsy rates were statistically significantly higher among Black vs White men (incidence rate ratio, 2.25; 95% CI, 2.06-2.46; P < .001). There was no change in biopsy rates associated with race at the onset of the pandemic nor during the recovery period from March 2020 to March 2021. Similar trends were observed for PC diagnosis rates. CONCLUSIONS AND RELEVANCE Results of this cohort study demonstrate that during the COVID-19 pandemic, prostate biopsy and PC diagnosis rates decreased, particularly during the peak of the pandemic. However, there were no statistically significant changes in rates by race.
UR - http://www.scopus.com/inward/record.url?scp=85128894276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128894276&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2022.0467
DO - 10.1001/jamaoncol.2022.0467
M3 - Article
C2 - 35389461
AN - SCOPUS:85128894276
SN - 2374-2437
VL - 8
SP - 914
EP - 918
JO - JAMA oncology
JF - JAMA oncology
IS - 6
ER -